Biogen Inc., a leading biopharmaceutical company, has recently announced significant interim biomarker data that further supports the potential benefits of SPINRAZA (nusinersen) in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after gene therapy. This breakthrough therapy has shown promise in addressing axonal injury and neurodegeneration, offering hope to patients and their families.
In the Phase 4 RESPOND study led by Biogen, interim 6-month biomarker data from the initial 29 participants have demonstrated positive clinical outcomes and safety following treatment with SPINRAZA. The study aims to evaluate the effectiveness of SPINRAZA over a 2-year period in infants and toddlers with SMA who have not responded adequately to treatment with Zolgensma (onasemnogene abeparvovec).
The key finding from the study is the remarkable reduction of plasma neurofilament light chain (NfL) levels in almost all study participants treated with SPINRAZA. NfL has been established as an biomarker for axonal injury and neurodegeneration, making this reduction a highly promising observation. The specific implications of this biomarker reduction will be presented at the prestigious 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference held from March 3-6, 2024.
Biogen’s commitment to addressing unmet clinical needs in the field of neurodegenerative diseases extends beyond spinal muscular atrophy. The company has recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its therapy, SKYCLARYS (omaveloxolone), to treat Friedreich’s ataxia (FA). This rare, genetic, progressive neuromuscular disease affects individuals aged 16 years and older. If approved by the European Commission (EC), SKYCLARYS will become the first authorized treatment for FA within the European Union.
Assessing the Impact on the Company:Biogen’s latest interim biomarker data reinforces the potential of SPINRAZA as a beneficial treatment for infants and toddlers with SMA who require further clinical intervention after gene therapy. This promising update not only solidifies Biogen’s position in the neurodegenerative field but also presents an opportunity to improve the quality of life for patients suffering from SMA.
Additionally, the CHMP’s positive opinion for SKYCLARYS represents a major milestone for Biogen. If approved by the EC, SKYCLARYS will enter the European market as the first authorized treatment for Friedreich’s ataxia. This achievement will not only provide a much-needed therapy for patients but also enhance Biogen’s reputation as a pioneer in the treatment of rare neurodegenerative diseases.
Comments